Keywords: Eisai, AkaRx, MGI Pharma, AKR-501, Thrombosytopenia, M&A

Eisai exercises option to buy AkaRx, for $255, along with rights to thrombocytopenia drug AKR-501

Article | 21 December 2009

Print This

Japanese drug major Eisai has said it will initiate procedures to acquire New Jersey, USA-based AkaRx under a deal valuing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in